In an effort to stimulate the development of new antibiotics, Britain’s National Health Service (NHS) yesterday announced the launch of a trial for a new pilot program that will pay drug companies for antibiotics using a subscription-style model.
Under the program, NHS will pay pharmaceutical companies up front for access to effective antibiotics, rather than reimbursing them based on the quantity of antibiotics sold. The idea behind the program is to delink profit from the volume sold, pay for antibiotics based on their public health value, and encourage the development of new antibiotics.
Under the new model, drug makers would still be reimbursed by the NHS even if the new drugs are kept in reserve.
The trial will be led by NHS and the National Institute for Health and Care Excellence (NICE). The agencies are asking pharmaceutical companies to identify antibiotics for the first phase of the program.
Read more at CIDRAP…